Aldehyde dehydrogenase serves as a biomarker for worse survival profiles in ovarian cancer patients: an updated meta-analysis

Yan Xia, Xuemin Wei, Hui Gong* and Yunxiang Ni*

Abstract

Background: The purpose of this comprehensive meta-analysis was to assess the association of aldehyde dehydrogenase (ALDH) expression with overall survival (OS) and disease-free survival (DFS)/progression-free survival (PFS) in ovarian cancer patients.

Methods: Systematic searches of Pubmed databases was performed to identify relevant literature published before February 28, 2018. A total of 14 studies (13 articles) with 2210 ovarian cancer patients were pooled. All included studies were performed by using Immunohistochemistry (IHC) for detection of ALDH expression. Hazard ratio (HR) and 95% confidence interval (CI) were extracted from included studies to evaluate the correlation of ALDH expression with OS and DFS/PFS.

Results: High expression of ALDH was associated with worse OS (HR: 1.43; 95% CI: 1.18–1.73) and poor DFS/PFS (HR: 1.55, 95% CI: 1.12–2.14). No evidence of publication bias was observed in OS (Begg's test, P = 0.113; Egger's test, P = 0.355) and DFS/PFS (Begg's test, P = 0.655; Egger's test, P = 0.189) in ovarian cancer patients. The subgroup of studies with cut-off value of low expression showed that high expression of ALDH was correlated with poor OS (HR: 1.36; 95% CI: 1.14–1.62) and DFS/PFS (HR: 1.79; 95% CI: 1.45–2.20) in ovarian cancer patients, with no observed heterogeneity (OS: I² = 0%, P = 0.45; DFS/PFS: I² = 0%, P = 0.55).

Conclusion: In conclusion, high expression of ALDH is correlated with worse survival profiles in ovarian cancer patients, indicating that ALDH might act as a potential molecular biomarker for prognosis of ovarian cancer.

Keywords: Aldehyde dehydrogenase (ALDH), Overall survival, Disease free survival, Ovarian cancer, Meta-analysis

Background

Ovarian cancer is one of the common gynecological malignancies featured by several symptoms (including bloating, pelvic pain, abdominal swelling as well as loss of appetite) [1–4]. It has been reported to be the seventh frequently diagnosed cancer and the fourth commonest causes of cancer-related death [1–4]. According to statistical reports, ovarian cancer occurs approximately 239,000 new cases as well as causes estimated 151,900 deaths worldwide in 2012, and happens nearly 52,100 new cases as well as results in 22,500 deaths in China during 2015 [1–4]. Owning to obscure symptoms at an early stage, fast progression, wide metastasis and high recurrence, the prognosis of ovarian cancer patients is far less satisfaction although improvement has been achieved in the disease management (such as imaging, histopathology, surgery as well as chemotherapy) [1]. Hence, further exploration related to additional and convincing biomarkers is imperative to supervise tumor progression for the promotion of prognosis in ovarian cancer patients.

Cancer stem cells (CSCs) are considered as a small class of tumor cells mass with self-renewing capacity, heterogeneity as well as resistance to chemotherapy/ radiotherapy, which play critical roles in tumor initiation, progression...
and maintenance [5, 6]. As one of the most common markers of CSCs, aldehyde dehydrogenase (ALDH) involves in the tumor development and progression processes of various carcinomas, including breast cancer, colorectal cancer, prostate cancer as well as bladder cancer [7–10]. Also, there are several clinical trials investigating the correlation of ALDH expression with the prognosis in ovarian cancer patients, whereas controversial results still existed [11–13]. Regarding that these controversial results might be caused by relatively small sample size, different inclusion criteria, outcomes assessed measures or other factors in different clinical studies, the comprehensive meta-analyses are needed. Although there is one previous meta-analysis including 1258 ovarian cancer patients from 7 studies (6 articles) in 2013, the number of included patients and studies is still relatively small [14]. Thus we performed additional comprehensive meta-analysis including 14 studies (13 articles) with 2210 ovarian cancer patients, and the purpose was to assess the association of ALDH expression with overall survival (OS) and disease-free survival (DFS)/progression-free survival (PFS) in ovarian cancer patients.

**Methods**

**Literature search strategy**

Based on the standard meta-analysis guidelines, we performed systematic searches of the National Center for Biotechnology Information (NCBI) Pubmed databases to identify relevant literature published before February 28, 2018 [15]. The studies were searched by using the following keywords in various combinations: Ovarian AND (neoplasm OR carcinoma OR cancer OR Tumor) AND (ALDH OR Aldehyde Dehydrogenase). Meanwhile, the reference lists of relevant articles were also manually retrieved.

**Selection criteria**

The criteria for inclusion were as follows: (1) All patients were diagnosed as ovarian cancer by pathological findings. (2) The association of ALDH expression with OS, DFS or PFS was investigated. (3) ALDH expression was detected by Immunohistochemistry (IHC). The criteria for exclusion were as follows: (1) The studies about animals or cell lines. (2) Articles were reviews, letters, case reports, editorials as well as expert opinions. (3) The studies were lack of essential information related to survival. All articles from the NCBI Pubmed databases are English, and there was no geographic location restriction. This meta-analysis was designed according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement [16]. This was a meta-analysis, which was not registered on ClinicalTrials.gov or similar repositories.

**Data extraction and quality assessment**

The studies were selected, and the data were extracted independently by two authors. The following information was recorded: author’s name, publish year, country, patients size, histology and disease stage, survival data, cut-off value (There were 3 studies set cut-off class as high expression (> 20%), 6 studies defined cut-off class as low expression (≤20%) and 5 studies installed cut-off class as IRS), Hazard ratio (HR), 95% confidence interval (CI), and so on. Survival data included OS, DFS as well as PFS, and there were 13 studies for OS, 6 studies for DFS and 4 studies for PFS. Considering the number of studies related to DFS or PFS was relatively small, which might poor statistical power in this meta-analysis, thus, the survival data was classified as OS and DFS/PFS for final analysis, this classified method was similar with the method from previous study conducted by Feng et al. [17]. Any disagreement was settled by a third reviewer. In addition, the items were treated as “Not available (NA)” if above data were not collected in the original articles. The Newcastle-Ottawa quality assessment scale was utilized to evaluate the methodological quality of studies included in this meta-analysis [18]. This scale refers to the evaluation of patient size, selection, study comparability, follow-ups as well as outcomes. Interpretation of the scale was carried out by stars that subsequently were added up and utilized for the comparison of study quality in a quantitative manner.

**Statistics**

All statistical analyses were performed with “meta” package in R. The major outcomes for this meta-analysis were the correlation of ALDH expression with OS and DFS/PFS in ovarian cancer patients. Some studies directly provided HR and 95% CI, while as to some other studies which did not give these data clearly, we used Engauge Digitizer version 4.1 and the relevant methods for calculation from available data or Kaplan-Meier survival cure [19] (free software download from http://sourceforge.net). In addition, we selected the multivariate analysis if there were univariate analysis and multivariate analysis. Chi-squared test was used for the evaluation of heterogeneity that was assessed by I^2 value, and I^2 value < 50% was considered as no or moderate heterogeneity, while I^2 value > 50% was considered as statistically significant heterogeneity. The significant heterogeneity was detected by using a random-effects model. Otherwise, the fixed effects model was used [20]. The possibility of published bias was assessed by Begg’s test and Egger’s test [21, 22]. The stability of pooled results was examined by Sensitivity analysis. Moreover, HR > 1 was considered as a worse survival, and when the 95% CI did not overlap with 1, the influence of high ALDH expression on survival implied statistically significant. All
the \( p \)-values were two-sided, and \( p < 0.05 \) was considered statistically significant.

**Results**

**Literature search analysis**

A total of 120 articles were initially identified as appropriate through database searching, while 101 articles were excluded by reviewing title or abstract, including 90 articles which were irrelevant, 9 articles which were reviews and 2 articles which did not record survival data. The remaining 19 articles were further assessed by reviewing the full-text, whereas 6 articles were excluded, including 3 articles that ALDH was detected by PCR, 2 articles that ALDH was detected by flow cytometry and 1 article that ALDH was detected by immunofluorescence. Finally, there were 13 articles (14 studies) included in the final meta-analysis (Fig. 1).

**Characteristics of the included studies**

The main characteristics of 14 studies (13 articles) included in this meta-analysis were summarized in Table 1. All studies were published from 2009 to 2018 with the sample size ranging from 37 to 440. There were 4 studies from China, 4 from USA, 3 from Japan, 2 from Germany and 1 from Norway. In addition, 5 studies defined the cut off value by complex score combining intensity, while others used the percentage of ALDH expression to define the cut off value. Detailed information of these studies was shown in Table 1.

**Correlation of ALDH expression with OS in ovarian cancer**

High expression of ALDH was associated with worse OS (HR:1.43; 95% CI: 1.18–1.73) (Fig. 2). No significant heterogeneity was found among the studies using the fixed effects model (\( I^2 = 35\% , P = 0.10 \)).

**Correlation between ALDH expression with OS in subgroup analysis with different cut-off class**

The results of subgroup meta-analysis of studies were shown in Fig. 3. The subgroup of studies with cut-off value of low expression (HR: 1.36; 95% CI: 1.14–1.62) and infrequent restriction site (IRS) expression (HR: 1.33; 95% CI: 1.17–1.52) showed that high expression of ALDH was correlated with poor OS in ovarian cancer patients, with no observed heterogeneity (low expression of ANRIL: \( I^2 = 0\% , P = 0.45 \); IRS expression of ANRIL: \( I^2 = 41\% , P = 0.17 \)). However, the subgroup of studies with cut off value of high expression revealed that there was no association of ALDH expression with OS in ovarian cancer patients (HR: 1.40; 95%CI: 0.67–2.92), and significant heterogeneity existed using the random effects model (\( I^2 = 63\% , P = 0.07 \)).

**Funnel plot to assess publication bias for the association of ALDH and OS in ovarian cancer**

Publication bias was evaluated by the Begg’s funnel plot and Egger’s test, which showed that the shape of the funnel plot was not obvious asymmetric, indicating no evidence of publication bias in OS of patients with ovarian cancer (Begg’s test, \( P = 0.113 \); Egger’s test, \( P = 0.355 \)) (Fig. 4).

**Sensitivity analysis of studies evaluating OS**

Sensitivity analysis was performed for the stability of the crude results, which showed that poor HR was not changed, and omitting Chang 2009 had a numerically great impact on OS compared to omitting other studies. Therefore, these results suggested that the conclusion was stable (Fig. 5).

**Correlation of ALDH expression with DFS/PFS in ovarian cancer**

As presented in Fig. 6, ALDH upregulation was correlated with poor DFS/PFS (HR: 1.55, 95% CI: 1.12–2.14). Owing to significant heterogeneity among the studies (\( I^2 = 72\% , P < 0.01 \)), the random effects model was performed for the calculation of the pooled HR with corresponding 95% CI.

**Correlation between ALDH expression with DFS/PFS in subgroup analysis with different cut-off class**

As shown in Fig. 7, subgroup meta-analysis of studies with cut off value of low expression disclosed that high ALDH expression was associated with worse DFS/PFS (HR: 1.79; 95% CI: 1.45–2.20), which was without obvious heterogeneity by using the fixed effects model (\( I^2 = 0\% , P = 0.55 \)). Whereas the subgroups meta-analysis of studies with cut off value of high expression (HR: 1.28;
### Table 1: Basic characteristics of all studies included in this meta-analysis

| Author       | Country | Year | Sample size | Cutoff | Cutoff class | Survival | HR (95% CI) | HR | HR_low | HR_high | Analysis |
|--------------|---------|------|-------------|--------|--------------|----------|-------------|----|--------|---------|----------|
| Yu           | China   | 2017 | 207         | IRS ≥ 3 | IRS          | OS       | 1.86 (1.16–2.98) | 1.86 | 1.16   | 2.98    | Multivariate |
| Huang        | Norway  | 2015 | 248         | IRS ≥ 7 | IRS          | OS       | 0.913 (0.735–1.134) | 0.913 | 0.735  | 1.134   | Multivariate |
| Mizuno       | Japan   | 2015 | 81          | ≥10%    | low          | OS       | 1.765 (0.874–2.984) | 1.765 | 0.874  | 2.984   | Univariate |
| Madhuchhanda | USA     | 2017 | 124         | ≥5%     | low          | OS       | 1.127 (0.903–1.564) | 1.127 | 0.903  | 1.564   | Univariate |
| Ruscito      | Germany | 2017 | 112         | IRS ≥ 2 | IRS          | OS       | 1.707 (1.012–2.881) | 1.707 | 1.012  | 2.881   | Multivariate |
| Chen         | China   | 2015 | 80          | ≥10%    | low          | OS       | 2.684 (1.149–6.249) | 2.684 | 1.149  | 6.249   | Univariate |
| Sun          | China   | 2015 | 100         | IRS ≥ 9 | IRS          | PFS      | 2.574 (1.297–5.638) | 2.574 | 1.297  | 5.638   | Univariate |
| Chang        | USA     | 2009 | 440         | > 20%   | high         | OS       | 0.92 (0.67–1.27)   | 0.92  | 0.67   | 1.27    | Multivariate |
| Deng         | USA     | 2010 | 439         | ≥10%    | low          | OS       | 1.27 (1.03–1.56)   | 1.27  | 1.03   | 1.56    | NA       |
| Landen       | USA     | 2010 | 65          | > 1%    | low          | OS       | 1.39 (0.69–2.80)   | 1.39  | 0.69   | 2.8     | Univariate |
| Wang         | China   | 2012 | 84          | > 50%   | high         | OS       | 2.43 (1.12–5.28)   | 2.43  | 1.12   | 5.28    | Multivariate |
| Liebscher    | Germany | 2013 | 131         | IRS ≥ 4 | IRS          | OS       | 2.01 (1.03–3.93)   | 2.01  | 1.03   | 3.93    | Multivariate |
| Kuroda       | Japan   | 2013a| 62          | > 20%   | high         | OS       | 1.63 (0.34–7.89)   | 1.63  | 0.34   | 7.89    | Univariate |
| Kuroda       | Japan   | 2013b| 37          | > 15%   | low          | OS       | 3.62 (0.47–27.88)  | 3.62  | 0.47   | 27.88   | Univariate |

HR: Hazard ratio; CI: confidence interval; OS: overall survival; PFS: progression-free survival; DFS: disease free survival; IRS: Infrequent restriction site; NA: Not available.

**Fig. 2** Forest plots of studies assessing the correlation between ALDH expression and OS. ALDH: Aldehyde dehydrogenase; HR: Hazard ratio; CI: confidence interval; OS: overall survival.
95% CI: 0.66–2.48) as well as IRS expression (HR: 1.56; 95% CI: 0.63–3.85) illustrated no correlation of ALDH expression with DFS/PFS in ovarian cancer patients, and heterogeneity was observed using the random effects model (high expression of ANRIL: I^2 = 74%, P = 0.02; IRS expression of ANRIL: I^2 = 75%, P = 0.05).

### Discussion

Malignant tumor has been identified to be consisted of a heterogeneous population of cells, among which, CSCs are a small group of cells presenting with high tumor-initiating potential, which devote into high tumor recurrence and worse distant metastasis in patients with various carcinomas, implying that the elimination of CSCs is essential for improvement of prognosis in these cancer patients [11]. In order to distinguish CSCs from a larger number of cancer cells, there are different methods including utilization of markers in cells surface (such as CD44, CD 90 or CD133), side population (SP) assay as well as ALDEFLUOR assay related to ALDH1 enzyme activity [23–26].

As a common marker of CSCs, ALDH possesses the responsibility to catalyze the oxidation of aldehyde, subsequently contributing to cellular homeostasis, which has been identified to be related to the function as stem cells such as self-renewal capability and stress-resistant properties [7, 25]. Although upregulation of most CSCs markers plays an important role in worse prognosis in cancer patients, several contradictions still exist on the

### Funnel plot to assess publication bias for the association of ALDH and DFS/PFS in ovarian cancer

The Begg’s funnel plot and Egger’s test presented no publication bias in IRS of patients with ovarian cancer across the included studies (Begg’s test, P = 0.655; Egger’s test, P = 0.189) (Fig. 8).

### Sensitivity analysis of all the studies assessing DFS/PFS

Sensitivity analysis revealed that pooled HR of DFS/PFS was not impacted by the exclusion of any single study, although omitting Chang 2009 had a numerically great influence on IRS compared to omitting other studies (Fig. 9).
putative CSC-marker ALDH expression in published studies. In order to clarify this problem, only one previous meta-analysis has examined the influence of ALDH on the survival of ovarian cancer patients and discloses that elevated ALDH expression is an independent risk factor for prognosis in ovarian cancer patients [14]. However, that previous meta-analysis just includes 7 studies (6 articles) with a total of 1258 ovarian cancer patients and is published in 2013, whose sample size is relatively small and the published time is relatively early.

Therefore, in this comprehensive meta-analysis, we analysed 14 studies (13 articles) with 2210 ovarian cancer patients, among these, 6 studies revealed that high expression of ALDH was associated with poor OS, 4 studies concluded that ALDH expression was positively correlated with DFS/PFS, and Deng et al. showed ALDH was unfavorable factors on both OS and DFS/PFS in ovarian cancer patients [12, 27–34]. However, there were 4 studies that support no association of ALDH with the survival of ovarian cancer [7, 35–37].
In addition, subgroup analysis by different cut-off class also presented with several interesting discovers, which showed correlation of high ALDH expression with poor OS and DFS/PFS when studies set the cut off class as low expression, but not high expression in ovarian cancer patients, which implied that ALDH expression existed in a small subpopulation of cancer cells, and we guessed when the cut-off class is defined as high expression of ALDH, most of ovarian cancer patients with intermediate ALDH expression are excluded and assigned to low expression group.

In this meta-analysis, we performed funnel plot and sensitivity analysis to assess publication bias and the stability of the crude results, and we discovered no evidence of publication bias in OS as well as DFS/PFS of patients with ovarian cancer, and pooled HR of OS as well as DFS/PFS was not impacted by the exclusion of any single study, although omitting Chang 2009 had a

| Study       | Hazard Ratio | HR 95%-CI | Weight (fixed) | Weight (random) |
|-------------|--------------|-----------|----------------|-----------------|
| Chang 2009  | 0.79         | [0.61; 1.02] | 31.9%          | 14.8%           |
| Deng 2010   | 1.77         | [1.37; 2.29] | 31.9%          | 14.9%           |
| Landen 2010 | 2.03         | [1.16; 3.56] | 6.7%           | 10.9%           |
| Wang 2012   | 1.70         | [0.77; 3.76] | 3.3%           | 8.2%            |
| Kuroda 2013a| 1.95         | [0.95; 4.00] | 4.1%           | 9.0%            |
| Kuroda 2013b| 3.97         | [0.60; 26.23] | 0.6%           | 2.5%            |
| Huang 2015  | 1.02         | [0.60; 1.73] | 7.6%           | 11.4%           |
| Mizuno 2015 | 2.13         | [1.17; 3.88] | 5.9%           | 10.4%           |
| Sun 2015    | 2.57         | [1.23; 5.37] | 7.6%           | 11.4%           |
| Madhuchhanda 2017 | 1.10 | [0.54; 2.24] | 4.1%           | 9.1%            |

Fixed effect model: 1.34 [1.16; 1.55] 100.0%  --
Random effects model: 1.55 [1.12; 2.14] 100.0%

Fig. 6 Forest plots of studies assessing the correlation between ALDH expression and DFS/PFS. ALDH, Aldehyde dehydrogenase; HR, Hazard ratio; CI, confidence interval; DFS, disease-free survival; PFS, progression-free survival

Fig. 7 Subgroup meta-analysis of studies with different cut-off value assessing the association of ALDH expression and DFS/PFS. ALDH, Aldehyde dehydrogenase; HR, Hazard ratio; CI, confidence interval; DFS, disease-free survival; PFS, progression-free survival
numerically great influence on IRS compared to omitting other studies, thus, the conclusion was stable. However, further meta-analysis including new relevant studies is greatly needed for validation.

The underlying mechanism of the correlation between evaluated ALDH expression and worse prognosis in ovarian cancer is still unclear. However, there are several relevant experiments disclosing that ALDH contributes to the processes of tumor development and progression through the influence on cells proliferation, cells apoptosis, cells migration as well as cells invasion. For instance, an interesting experiment displays that ALDH (hi)CD44(+)CD24(−) and ALDH (hi)CD44(+)CD133(+) cells present with enhanced tumorigenicity and metastasis compared to ALDH(low)CD44(low/−) cells, indicating that high ALDH serves as an important role in the enhanced malignant and metastatic ability of breast cancer cells [38]. Another in vitro study reveals that ALDH

| Study                        | HR   | 95% CI      |
|------------------------------|------|-------------|
| Omitting Chang 2009          | 1.72 | [1.44; 2.05]|
| Omitting Deng 2010           | 1.18 | [0.99; 1.41]|
| Omitting Landen 2010         | 1.30 | [1.12; 1.51]|
| Omitting Wang 2012           | 1.33 | [1.15; 1.54]|
| Omitting Kuroda 2013a        | 1.32 | [1.14; 1.53]|
| Omitting Kuroda 2013b        | 1.33 | [1.15; 1.54]|
| Omitting Huang 2015          | 1.37 | [1.18; 1.60]|
| Omitting Mizuno 2015         | 1.30 | [1.12; 1.51]|
| Omitting Sun 2015            | 1.31 | [1.13; 1.52]|
| Omitting Madhuchhanda 2017   | 1.35 | [1.17; 1.57]|
| Fixed effect model           | 1.34 | [1.16; 1.55]|

Fig. 8 Funnel plot for the publication bias test of included studies for ALDH expression and DFS/PFS. ALDH, Aldehyde dehydrogenase; DFS, disease-free survival; PFS, progression-free survival

Fig. 9 Sensitivity analysis for evaluating the correlation between ALDH expression and DFS/PFS. ALDH, Aldehyde dehydrogenase; HR, Hazard ratio; CI, confidence interval; DFS, disease-free survival; PFS, progression-free survival
(high) CD44(+) cells exhibit a higher proliferative, clonogenic and metastatic capacity compared to ALDH(low) CD44(−) cells, suggesting that ALDH has higher tumorigenicity capacity in prostatic cancer [39]. Therefore, ALDH might act as an oncogene in several carcinomas. Although some interesting results were found in this meta-analysis, some limitations still existed. At first, there were 14 studies included in this comprehensive meta-analysis, and the numbers of studies were relatively small. Meanwhile, all ovarian cancer patients from this meta-analysis were just from five countries (including China, USA, Germany, Japan as well as Norway). In addition, significant heterogeneity still existed partly due to different characteristics of subjects, different cut off value of ALDH expression or other factors, which might lead to confounding bias. Furthermore, subgroup analyses of studies with other characteristics such as historical type, study region or follow-up duration were not carried out. Further meta-analysis included larger-scale studies is necessary.

Conclusions
In conclusion, high expression of ALDH is correlated with worse survival profiles in ovarian cancer patients, indicating that ALDH might act as a potential molecular biomarker for prognosis of ovarian cancer.

Abbreviations
ALDH: Aldehyde dehydrogenase; CI: Confidence interval; CSCs: Cancer stem cells; DFS: Disease-free survival; HR: Hazard ratio; IHC: Immunohistochemistry; NA: Not available; NCBI: National Center for Biotechnology Information; OS: Overall survival; PFS: Progression-free survival; PRISMA: Preferred Reporting Items for Systematic reviews and Meta-Analyses; SP: Side population

Funding
Not applicable.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
YY and HG developed the survey, analysed and interpreted the data. XW and YN made substantial contributions to the writing of the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 7 August 2018 Accepted: 20 November 2018
Published online: 06 December 2018

References
1. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–88.
2. Cramer DW. The epidemiology of endometrial and ovarian cancer. Hematol Oncol Clin North Am. 2012;26(1):1–12.
3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2013;63(2):74–100.
4. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):10–26.
5. Beck B, Blapain C. Unravelling cancer stem cell potential. Nat Rev Cancer. 2013;13(10):727–38.
6. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ikhuwakawa F, Schuringa JJ, Stassi G, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012;12(11):767–75.
7. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009;69(8):3382–9.
8. Carpentino JE, Hynes MJ, Appelman HD, Zheng T, Steindler DA, Scott EW, Huang EH. Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res. 2009;69(20):6208–15.
9. Su Y, Otu Q, Zhang X, Jiang Z, Leng Q, Liu Z, Stass SA, Jiang F. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomark Prev. 2010;19(2):327–37.
10. van den Hoogen C, van der Horst G, Buijs JT, Lippitt JM, van den Hoogen CJ, van der Horst G, Buijs JT, Lippitt JM, van den Hoogen CJ, van der Horst G, Buijs JT, Lippitt JM. Prognostic value of microRNA-214 in multiple human cancers: a meta-analysis of observational studies. Oncotarget. 2017;8(43):75350–60.
11. Kuroda T, Hirohashi Y, Toriboe T, Yasuda K, Takahashi A, Asanuma H, Morita R, Manya T, Asano T, Muzuchi M, et al. ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis. PLoS One. 2013;8(6):e65158.
12. Chang B, Liu G, Xiao L, Rosen DG, Wang X, Liu J. ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol. 2009;22(6):817–23.
13. Ricci F, Bernasconi S, Porcu L, Erba E, Panini N, Frusci R, Sina F, Torri V, Broglini M, Damia G. ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. Am J Cancer Res. 2013;3(2):221–9.
14. Liu S, Liu C, Min X, Ji Y, Wang N, Liu D, Cai J, Li K. Prognostic value of cancer stem cell marker aldehyde dehydrogenase in ovarian cancer: a meta-analysis. PLoS One. 2013;8(11):e81050.
15. Liberati A, Altman DG, Tetzlaff J, Mucrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
16. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
17. Feng Y, Duan F, Liu W, Fu X, Cui S, Yang Z. Prognostic value of the microRNA-214 in multiple human cancers: a meta-analysis of observational studies. Oncotarget. 2017;8(43):75350–60.
18. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–8.
19. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.
22. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.
23. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396–401.

24. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183(4):1797–806.

25. Ginestier C, Hauru MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67.

26. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755–68.

27. Yu L, Zhu B, Wu S, Zhou L, Song W, Gong X, Wang D. Evaluation of the correlation of vasculogenic mimicry, ALDH1, KISS-1, and MACC1 in the prediction of metastasis and prognosis in ovarian carcinoma. Diagn Pathol. 2017;12(1):23.

28. Mizuno T, Suzuki N, Makino H, Furui T, Morii E, Aoki H, Kunisada T, Yano M, Kaji S, Hirashima Y, et al. Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species. Gynecol Oncol. 2015;137(2):299–305.

29. Ruscito I, Caciser Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Ganapathi RN, Glajzer J, Kulbe H, Trillsch F, et al. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the ovarian Cancer therapy-innovative models prolong survival (OCTIPS) consortium. Eur J Cancer. 2017;92:14–25.

30. Sun Y, Jia X, Wu X. High expressions of Lgr5 and ALDH1 in primary epithelial ovarian cancer correlate with advanced tumor stage and grade as well as poor prognosis of the patients. Gynecol Obstet Invest. 2016;81:162–168.

31. Deng S, Yang X, Lirisus H, Liang S, Kaur S, Ye Q, Li C, Wang LP, Roby KF, Orsulic S, et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One. 2010;5(4):e10277.

32. Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Genthenson DM, et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010;9(12):3386–99.

33. Wang YC, Yo YT, Lee HY, Liao YP, Chao TK, Su PH, Lai HC. ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am J Pathol. 2012;180(3):1159–69.

34. Liebscher CA, Prinzler J, Sinn BV, Budczies J, Denkert C, Nourse A, Sehouli J, Bradic E, Dietel M, Darb-Esfahani S. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma. Hum Pathol. 2013;44(8):1465–71.

35. Huang R, Li X, Holm R, Trope CG, Nesland JM, Suo Z. The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study. BMC Cancer. 2015;15:502.

36. Roy M, Connor J, Al-Niaimi A, Rose SL, Mahajan A. Aldehyde dehydrogenase 1A1 (ALDH1A1) expression by immunohistochemistry is associated with chemo-refractoriness in patients with high-grade ovarian serous carcinoma. Hum Pathol. 2018;73:1–6.

37. Chen PX, Li QH, Yang Z. Musashi-1 expression is a prognostic factor in ovarian adenocarcinoma and correlates with ALDH-1 expression. Pathol Oncol Res. 2015;21(4):1133–40.

38. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 2009;13(8B):2236–52.

39. Yu C, Yao Z, Dai J, Zhang H, Escara-Wilke J, Zhang X, Keller ET. ALDH activity indicates increased tumorigenic cells, but not cancer stem cells, in prostate cancer cell lines. In Vivo. 2011;25(1):69–76.